Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | PTGES | O14684 | 1/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 9/20 | 0.53 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.49 |
| ▸ | GNA15 | P30679 | 1/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.48 |
| ▸ | PPARA | Q07869 | 2/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | EPOR | P19235 | 1/20 | 0.46 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.46 |
| ▸ | CALM1 | P0DP23 | 1/20 | 0.45 |
| ▸ | CAMKK2 | Q96RR4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6511831 | 0.95 | FFAR1 (0.57) | TSHRHSD17B10PTGESFFAR1FFAR4 | |
| SCHEMBL6515378 | 0.94 | FFAR1 (0.52) | TSHRHSD17B10PTGESFFAR1FFAR4 | |
| SCHEMBL6509273 | 0.93 | MEP1B (0.53) | TSHRHSD17B10PTGESFFAR1FFAR4 | |
| SCHEMBL6507836 | 0.91 | FFAR1 (0.49) | TSHRHSD17B10PTGESFFAR1PPARG | |
| SCHEMBL6528810 | 0.90 | FFAR1 (0.49) | TSHRHSD17B10PTGESFFAR1FFAR4 | |
| SCHEMBL6512693 | 0.89 | TSHR (0.49) | TSHRHSD17B10PTGESFFAR1FFAR4 | |
| SCHEMBL6510780 | 0.89 | TSHR (0.49) | TSHRHSD17B10PTGESFFAR1FFAR4 | |
| SCHEMBL6510191 | 0.88 | FFAR1 (0.52) | TSHRHSD17B10FFAR1NR3C1 | |
| SCHEMBL6511901 | 0.86 | TSHR (0.49) | TSHRHSD17B10PTGESFFAR1FFAR4 | |
| SCHEMBL6519131 | 0.85 | NR3C1 (0.55) | TSHRHSD17B10PTGESFFAR1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130203726-A1 | FtsZ INHIBITORS AS POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS | ROEMER TERRY (US) | 2013-08-08 | — | — | US | disclosed |
| US-20130203726-A1 | FtsZ INHIBITORS AS POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS | ROEMER TERRY (US) | 2013-08-08 | — | — | US | disclosed |
| WO-2005097100-A2 | ANTIBACTERIAL AGENTS | PROLYSIS LTD. (GB) | 2005-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203726-A1 | FtsZ INHIBITORS AS POTENTIATORS OF BETA-LACTAM ANTIBIOTICS AGAINST METHICILLIN-RESISTANT STAPHYLOCOCCUS | RCE1, POLE3, MCRS1 | TSHR 4210/4885HSD17B10 3389/4885PTGES 3074/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.